Takeda’s Pevonedistat Falters in Phase 3 Cancer Study

September 7, 2021

Takeda Pharmaceutical said that its investigational cancer drug pevonedistat did not meet the primary endpoint of event-free survival in a phase 3 clinical trial.

The trial of the potential blockbuster drug was designed to evaluate a combination of pevonedistat and Celgene’s chemotherapy drug azacitidine as a first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS), a rare form of bone marrow cancer, or chronic myelomonocytic leukemia or low-blast acute myeloid leukemia.

Pevonedistat is an enzyme inhibitor that leads to cancer cell death. Last year, the FDA granted it Breakthrough Therapy designation for patients with higher risk MDS.

View today's stories